UF startup Myosin Therapeutics, a biotechnology company developing novel therapies for aggressive cancers, announced it has been awarded a $4.5M Phase IIB Bridge Award from the National Cancer Institute’s (NCI) Small Business Innovation Research (SBIR) program.
The funding will support Myosin Therapeutic’s Phase I STAR-GBM dose escalation and expansion trial of MT-125, a first-in-class novel small molecule therapeutic being evaluated in patients with newly diagnosed, MGMT unmethylated glioblastoma. Glioblastoma remains among the most lethal cancers, with median survival measured in months. MT-125 targets non-muscle myosin II, a critical driver of tumor cell invasion, proliferation and treatment resistance, representing a novel therapeutic approach that is distinct from existing standards of care.
